公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2021 | Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations | Chang G.-C.; Lam D.C.-L.; Tsai C.-M.; Chen Y.-M.; JIN-YUAN SHIH ; Aggarwal S.; Wang S.; Kim S.-W.; Kim Y.-C.; Wahid I.; Li R.; Lim D.W.-T.; Sriuranpong V.; Chan R.T.-T.; Lorence R.M.; Carriere P.; Raabe C.; Cseh A.; Park K. | International Journal of Clinical Oncology | 2 | 2 |